

**Supplementary Table 1.** Treatments post-relapse with adjuvant anti-PD-1 therapy.

Characteristic	No IM CLND (n = 326)	IM CLND (N = 60)
Total relapses, no. (%)	<b>N= 97 (30%)</b>	<b>N=27 (45%)</b>
Treatments post-relapse, no. (%)		
Anti-PD-1 monotherapy	24 (25)	7 (26)
Ipi, ipi/nivo or ipi/pembro	30 (31)	6 (22)
BRAFi/MEKi	17 (18)	7 (26)
Other drugs	3 (3)	3 (11)
Intralesional	4 (4)	0 (0)
No treatment	22 (23)	3 (11)
Radiation therapy	19(20)	5(19)
Surgery for relapse	53 (55)	7(26)
Therapeutic lymph node dissection	31 (32)	N/A

**Abbreviations:** BRAFi/MEKi, BRAF/MEK inhibitor; CLND, completion lymph node dissection; Ipi, ipilimumab; Nivo, nivolumab; PD-1, programmed cell death protein; Pembro, pembrolizumab; N/A: not applicable..